|
(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.(b)(4).The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history identified no other incidents from this lot.The investigation determined the reported difficulty appears to be related to circumstances of the procedure.It was reported that the device was prepared inside of the patient anatomy.It should be noted coronary dilatation catheters (cdc), nc trek rx, global, instruction for use (ifu) states: caution: all air must be removed from the balloon and displaced with contrast prior to inserting into the body, otherwise, complications may occur.Based on the information reviewed, there is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.
|
|
It was reported that during preparation for treatment of a heavily calcified, 90% stenosed, 15mm-long lesion in the moderately tortuous 2.3mm-diameter right posterior descending coronary artery, a 2.25x12mm nc trek rx balloon dilatation catheter (bdc) was unpackaged without difficulty and the device soaked in saline.Air aspiration of the device was performed while inside of patient anatomy.The nc trek rx bdc was advanced to the lesion without resistance.During the 1st inflation the balloon ruptured at 15 atmospheres.The nc trek rx bdc was withdrawn without difficulty.Dilatation was completed using a 2.5x15 non-abbott bdc, followed by deployment of a non-abbot stent, resulting post-procedure stenosis of 15%.There were no adverse patient effects and no occurrence of a clinically significant delay.No additional information was provided.
|